ECP
RPRX icon

Epacria Capital Partners’s Royalty Pharma RPRX Stock Holding History

Epacria Capital Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,440
Closed -$574K – 41
2025
Q1 		$574K Sell
18,440
-750
-4% -$23.8K 0.47% 31
2024
Q4 		$490K Hold
19,190
– – 0.41% 36
2024
Q3 		$543K Buy
19,190
+4,026
+27% +$112K 0.37% 43
2024
Q2 		$400K Buy
+15,164
New +$420K 0.29% 45

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

Epacria Capital Partners's RPRX Position: Q2 2025 in Review

Epacria Capital Partners sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 18,440 shares — an estimated $574K sold.

Epacria Capital Partners first reported a position in RPRX in Q2 2024 and held it in 4 quarters. The position peaked at $574K in Q1 2025. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Epacria Capital Partners reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Epacria Capital Partners sold 18,440 Royalty Pharma shares in Q2 2025, an estimated $574K.
  • Epacria Capital Partners first reported a position in Royalty Pharma in Q2 2024 and held it in 4 quarters.
  • Epacria Capital Partners's Royalty Pharma position peaked at $574K in Q1 2025.
  • 455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Epacria Capital Partners's 13F filing for Q2 2025, filed 13 Aug 2025.